Shots:
- Lilly‘s global P-III (LIBRETTO-432) trial assessed Retevmo (selpercatinib; 160mg, BID) vs PBO in 151 pts with early-stage (IB-IIIA) RET fusion-positive NSCLC following completion of definitive radiotherapy or surgery with curative intent, & other adjuvant therapy
- Trial met the 1EP, improving the EFS by 83% in stage II–IIIA RET-positive NSCLC (n=109), with 24mos. EFS rates of 92% vs 61%; mEFS was not reached with selpercatinib vs 31.8mos. for PBO
- In the overall population, the trial showed 24mos. EFS rates of 94% vs 70%. Benefits were consistent across BICR & key subgroups, while OS showed a favorable trend but remained immature due to few events; data to be submitted to global health authorities & were published in The NEJM
Ref: Prnewswire | Image: Eli Lilly | Press Release
Related News: Eli Lilly Reports the P-Ib (Heart-2) Trial Data on VERVE-102 as a One-Time Treatment for Hypercholesterolemia
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
